These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 22760478)

  • 1. New disease-modifying therapies and new challenges for MS.
    Yadav V; Bourdette D
    Curr Neurol Neurosci Rep; 2012 Oct; 12(5):489-91. PubMed ID: 22760478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [[Natalizumab therapy, 2013].
    Karácsony M; Bencsik K; Vécsei L
    Ideggyogy Sz; 2014 Jul; 67(7-8):220-8. PubMed ID: 25509362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fingolimod and multiple sclerosis: four cautionary tales.
    Bourdette D; Gilden D
    Neurology; 2012 Nov; 79(19):1942-3. PubMed ID: 23035058
    [No Abstract]   [Full Text] [Related]  

  • 4. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et al.
    Tur C; Montalban X
    Mult Scler; 2014 Apr; 20(4):510-1. PubMed ID: 24468818
    [No Abstract]   [Full Text] [Related]  

  • 6. [Disease modifying drugs in multiple sclerosis and pregnancy].
    Tur C; Tintoré M; Aguilera C
    Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277
    [No Abstract]   [Full Text] [Related]  

  • 7. Multiple sclerosis reactivation postfingolimod cessation: is it IRIS?
    Alroughani R; Almulla A; Lamdhade S; Thussu A
    BMJ Case Rep; 2014 Oct; 2014():. PubMed ID: 25320259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E; Louapre C; Lubetzki C; Papeix C
    Mult Scler; 2014 Apr; 20(4):505-9. PubMed ID: 24367037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natalizumab to fingolimod washout in patients at risk of PML: when good intentions yield bad outcomes.
    Giovannoni G; Naismith RT
    Neurology; 2014 Apr; 82(14):1196-7. PubMed ID: 24610331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP; Martín-Medina P; Berenguer-Ruiz L; Pérez-Carmona N; Sanchez-Perez R; Polache-Vengud J; Feliu-Rey E
    Acta Neurol Scand; 2013 Aug; 128(2):e6-e10. PubMed ID: 23336398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe relapses under fingolimod treatment prescribed after natalizumab.
    Centonze D; Rossi S; Rinaldi F; Gallo P
    Neurology; 2012 Nov; 79(19):2004-5. PubMed ID: 23035063
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD; McQueen RB; Miravalle A; Corboy JR; Vollmer TL; Nair K
    Am J Manag Care; 2013 Apr; 19(4):278-85. PubMed ID: 23725360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.
    Cohen M; Maillart E; Tourbah A; De Sèze J; Vukusic S; Brassat D; Anne O; Wiertlewski S; Camu W; Courtois S; Ruet A; Debouverie M; Le Page E; Casez O; Heinzlef O; Stankoff B; Bourre B; Castelnovo G; Rico A; Berger E; Camdessanche JP; Defer G; Clavelou P; Al Khedr A; Zephir H; Fromont A; Papeix C; Brochet B; Pelletier J; Lebrun C;
    JAMA Neurol; 2014 Apr; 71(4):436-41. PubMed ID: 24566807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Lahoz R; Reynolds T; Korn JR
    Curr Med Res Opin; 2014 Aug; 30(8):1461-71. PubMed ID: 24754349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
    Cutter GR; Stüve O
    Mult Scler; 2014 Sep; 20(10):1304-5. PubMed ID: 24812045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
    J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing MS in a changing treatment landscape.
    Duddy M; Haghikia A; Cocco E; Eggers C; Drulovic J; Carmona O; Zéphir H; Gold R
    J Neurol; 2011 May; 258(5):728-39. PubMed ID: 21437661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy.
    Carruthers RL; Rotstein DL; Healy BC; Chitnis T; Weiner HL; Buckle GJ
    Mult Scler; 2014 Sep; 20(10):1381-90. PubMed ID: 24852928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab: risk stratification of individual patients with multiple sclerosis.
    Tur C; Montalban X
    CNS Drugs; 2014 Jul; 28(7):641-8. PubMed ID: 24942634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.